share_log

泽璟制药(688266.SH)：盐酸吉卡昔替尼片治疗重症斑秃III期临床试验达到主要疗效终点

Zejiang Pharmaceutical (688266.SH): The Phase III clinical trial of JAK inhibitor GDC-0853 hydrochloride tablets for the treatment of severe alopecia areata has reached the primary endpoint of therapeutic effect.

Gelonghui Finance ·  Jun 12 04:32

On June 12th, Gelonhui announced that Zejin Pharmaceutical (688266.SH) has achieved the primary efficacy endpoint of the Phase III clinical trial (plan number: ZGJAK018) for the treatment of severe alopecia areata with the newly developed Class 1 drug Gicasitini hydrochloride tablets (formerly known as Jacktin hydrochloride tablets). It reached statistical significance (p < 0.0001) in a multicenter, randomized, double-blind, placebo-controlled Phase III clinical trial on the efficacy and safety of Gicasitini hydrochloride tablets in the treatment of severe alopecia areata patients. The company will accelerate the launch process of Gicasitini hydrochloride tablets for the treatment of severe alopecia areata.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment